Merit Medical Systems, Inc.
NASDAQ•MMSI
CEO: Mr. Fred P. Lampropoulos
Sector: Healthcare
Industry: Medical - Instruments & Supplies
Listing Date: 1990-05-14
Merit Medical Systems, Inc. designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions. It also offers custom procedural solutions that include critical care products, disinfection protection systems, syringes, manifold kits, and trays and packs; coating services for medical tubes and wires; and sensor components for microelectromechanical systems. In addition, the company provides pulmonary products that consist of laser-cut tracheobronchial stents, over-the-wire and direct visualization delivery systems, and dilation balloons to endoscopically dilate structures; gastroenterology products, such as covered esophageal stents, syringe and gauges, and balloon dilators; and kits and accessories for endoscopy and bronchoscopy procedures. It sells its products to hospitals and alternate site-based physicians, technicians, and nurses through direct sales force, distributors, original equipment manufacturer partners, or custom procedure tray manufacturers. The company was incorporated in 1987 and is headquartered in South Jordan, Utah.
Contact Information
Market Cap
$4.03B
P/E (TTM)
31.3
56.1
Dividend Yield
--
52W High
$100.19
52W Low
$66.34
52W Range
Rank29Top 17.8%
5.2
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Average • 5.2 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025
Financial Dashboard
Q4 2025 Data
Revenue
$393.94M+0.00%
4-Quarter Trend
EPS
$0.64+0.00%
4-Quarter Trend
FCF
$76.99M+0.00%
4-Quarter Trend
2025 Annual Earnings Highlights
Key Highlights
Sales Growth Strong Net sales reached $1.516B USD, growing 11.8% driven by U.S. demand and favorable EMEA international sales trends.
Gross Margin Expansion Gross profit margin improved to 48.7% in 2025, up from 47.4% in 2024, reflecting favorable pricing and product mix.
Net Income Rises Net income totaled $128.5M USD, increasing from $120.4M USD in 2024; diluted EPS was $2.13 for the year.
Strategic Acquisitions Completed Completed Biolife merger and Pentax asset acquisition in 2025, integrating new hemostatic and cryotherapy technologies.
Risk Factors
Supply Chain Cost Volatility Reliance on third-party vendors for materials like resins creates risk from supply disruptions and rising commodity and transportation costs.
Geopolitical Trade Policy Risks Uncertainty from global trade policies, including China's VBP, may negatively impact pricing, sales volumes, and margins in 2026.
Regulatory Approval Uncertainty Lengthy, expensive FDA and foreign regulatory processes, especially MDR compliance, could delay or prevent new product commercialization.
Leadership Transition Challenges Recent CEO/President transition in October 2025 presents risks of operational inefficiency and loss of institutional knowledge.
Outlook
Focus on Global Growth Strategy targets enhancing global profitability via R&D, sales model optimization, and strict cost discipline across core divisions.
Product Innovation Cadence Commitment to innovation drives new product launches, leveraging cross-functional collaboration to accelerate introduction timelines.
Sustainability Initiatives Progress Implementing eWorq program to reduce paper usage, aiming for 93% adoption by 2026; maintaining ISO 14001 certifications.
Capital Spending Planned Anticipate capital expenditures of $80M to $100M in 2026, primarily for property and equipment construction projects.
Peer Comparison
Revenue (TTM)
$5.65B
$5.10B
$3.44B
Gross Margin (Latest Quarter)
94.9%
90.1%
89.8%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| KRYS | $7.65B | 37.0 | 18.7% | 0.7% |
| GKOS | $6.78B | -35.8 | -25.4% | 15.6% |
| ACLX | $6.71B | -28.2 | -55.4% | 15.9% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
3.5%
Moderate Growth
4Q Net Income CAGR
8.0%
Profitability Improving
Cash Flow Stability
100%
Strong Cash Flow
Deep Research
Next earnings:Apr 22, 2026
EPS:-
|Revenue:-
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement | LTM |
|---|
No Data